France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain

Nanobiotix SA

24/09/2026 21:24

Overview
France-based biotech firm's H1 2026 revenue declined due to prior year one-off non-cash impact
Net loss widened to €34.3 mln for H1 2026
Company raised ~€86 mln in May 2026, boosting cash to €110.9 mln and extending runway into 2029

Outlook
Company expects cash and cash equivalents of €110.9 mln to fund operations into 2029

Result Drivers
REVENUE DECLINE EXPLAINED - Co said H1 2026 revenue fell mainly due to absence of a one-off non-cash revenue item recognized in H1 2025 after transfer of NANORAY-312 study sponsorship to Johnson & Johnson
CLINICAL PROGRESS - Co reported promising early efficacy and safety data from JNJ-1900 (NBTXR3) studies in NSCLC and head and neck cancer
LOWER R&D AND SG&A EXPENSES - Co attributed reduced R&D and SG&A expenses to lower clinical activity after study sponsorship transfer and less patient recruitment

Company press release: ID:nGNXbZrKXK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Loss
 
EUR 34.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Nanobiotix SA is €52.00, about 86.1% above its September 24 closing price of €27.94

Reuters Recommended Reads
Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs
Sept 21 - AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)